# A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

> **NCT06185673** · PHASE1,PHASE2 · RECRUITING · sponsor: **Benitec Biopharma, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Oculopharyngeal Muscular Dystrophy

## Interventions

- **GENETIC:** BB-301: Dose escalation phase 1b cohort 1
- **GENETIC:** BB-301: Dose escalation phase 1b cohort 2
- **GENETIC:** BB-301: Dose escalation phase 1b cohort 3
- **GENETIC:** BB-301: Dose expansion phase 2a

## Key facts

- **NCT ID:** NCT06185673
- **Lead sponsor:** Benitec Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-28
- **Primary completion:** 2030-11
- **Final completion:** 2040-11
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06185673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06185673, "A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06185673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*